An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis
- Registration Number
- NCT01885078
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
The purpose of this study is to investigate the long-term safety and any side effects of baricitinib in participants who have completed a previous baricitinib rheumatoid arthritis study.
The study provides 7 years of additional treatment with baricitinib.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2877
- Have completed the final active treatment in study JADV (NCT01710358), JADZ (NCT01711359), JADX (NCT01721057), JADW (NCT01721044), JADA (NCT01185353) or JAGS (NCT02265705)
- Have significant uncontrolled cerebro-cardiovascular (eg, myocardial infarction [MI], unstable angina, unstable arterial hypertension, severe heart failure, or cerebrovascular accident), respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, neuropsychiatric disorders, or abnormal laboratory values that developed during a previous baricitinib study that, in the opinion of the investigator, pose an unacceptable risk to the participant if investigational product continues to be administered
- Have a known hypersensitivity to baricitinib or any component of this investigational product
- Had investigational product permanently discontinued at any time during a previous baricitinib study
- Had temporary investigational product interruption at the final study visit of a previous baricitinib study and, in the opinion of the investigator, this poses an unacceptable risk for participation in the study
- Have any other condition that, in the opinion of the investigator, renders the participant unable to understand the nature, scope, and possible consequences of the study or precludes the participant from following and completing the protocol
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 4 milligram (mg) Baricitinib Placebo 4 mg Baricitinib administered orally once daily. Participants received baricitinib doses according to the dose received at the completion of the originating study. Participants may continue to receive the background non-investigational, open-label conventional disease-modifying antirheumatic drugs (cDMARD), nonsteroidal anti-inflammatory drug (NSAID), corticosteroid, and other analgesic therapies they were receiving at completion of the originating study. 2 mg Baricitinib Placebo 2 mg Baricitinib administered orally once daily. Participants received baricitinib doses according to the dose received at the completion of the originating study. Participants may continue to receive the background non-investigational, open-label cDMARD, NSAID, corticosteroid, and other analgesic therapies they were receiving at completion of the originating study. 2 mg Baricitinib Step-down Baricitinib 2 mg Baricitinib administered orally once daily in the 96-week Step-down period. Participants may continue to receive the background non-investigational, open-label cDMARD, NSAID, corticosteroid, and other analgesic therapies they were receiving at completion of the originating study. 4 milligram (mg) Baricitinib Baricitinib 4 mg Baricitinib administered orally once daily. Participants received baricitinib doses according to the dose received at the completion of the originating study. Participants may continue to receive the background non-investigational, open-label conventional disease-modifying antirheumatic drugs (cDMARD), nonsteroidal anti-inflammatory drug (NSAID), corticosteroid, and other analgesic therapies they were receiving at completion of the originating study. 2 mg Baricitinib Baricitinib 2 mg Baricitinib administered orally once daily. Participants received baricitinib doses according to the dose received at the completion of the originating study. Participants may continue to receive the background non-investigational, open-label cDMARD, NSAID, corticosteroid, and other analgesic therapies they were receiving at completion of the originating study. 4 mg Baricitinib Step-down Baricitinib 4 mg Baricitinib administered orally once daily in the 96-week Step-down period. Participants may continue to receive the background non-investigational, open-label cDMARD, NSAID, corticosteroid, and other analgesic therapies they were receiving at completion of the originating study.
- Primary Outcome Measures
Name Time Method Number of Participants Who Experienced Adverse Events (AEs) or Serious AE Baseline through 84 Months An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can be any unfavorable and unintended sign (i.e., abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. Non-serious AEs are reported at a threshold of 5%.
An SAE is an AE from this study that results in any of the following: death, initial or prolonged inpatient hospitalization, a life-threatening experience, persistent or significant disability/incapacity, congenital anomaly/birth defect, considered significant by the investigator for any other reason
A summary of serious adverse events (SAEs) and other non-serious adverse events (AEs), regardless of causality, were reported in the Reported Adverse Events module.
- Secondary Outcome Measures
Name Time Method Percentage of Participants Maintaining American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean Remission Response Year 5 after entry into JADY Boolean-based definition of remission, all 4 criteria below must be met: tender joint count (TJC28 ) \<=1, swollen joint count (SJC28) \<=1, hsCRP \<=1 milligram per deciliter (mg/dL), Patient Global Assessment of Disease Activity using visual analog scale (VAS) \<=1 cm.
Change From Baseline of Originating Study in Joint Space Narrowing at Year 1 Baseline, Year 1 X-rays of the hands/wrists and feet were assessed for joint space narrowing (JSN) and bone erosions. Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, is scored from 0 to 4, with 0 indicating no (normal) JSN and 4 indicating complete loss of joint space, bony ankylosis or luxation. JSN scores ranged from 0-168. A score of 0 would indicate no change and higher scores represent a worsening of joint space narrowing.
Change From Baseline of Originating Study in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Scores (Self-Perceived Health) Baseline, Year 5 The European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. The second component is a self-perceived health score which is assessed using a VAS that ranged from 0 to 100 millimeter (mm), where 0 mm indicated the worst health you can imagine and 100 mm indicated the best health you can imagine.
Percentage of Participants Maintaining a Health Assessment Questionnaire Disability Index (HAQ-DI) Improvement ≥0.3 Year 5 after entry into JADY The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition.
An improvement of 0.22 or 0.3 points on the HAQ-DI has been identified as a minimal clinically important difference in Rheumatoid Arthritis participants.Change From Baseline of Originating Study in Bone Erosion Score Baseline, Year 5 The joint erosion score is a summary of erosion severity in 32 joints of the hands and 12 joints of the feet. The maximum erosion score for a hand joint is 5 and for a foot joint is 10. Thus, the maximal erosion score is 280 for a timepoint (160 for both hands/ wrists and 120 for both feet). Each joint is scored according to the surface area involved from 0 to 5 for hand joints and 0 to 10 for the foot joints. The highest score (5 for the hand and 10 for the foot) indicates extensive loss of bone from more than one half of the articulating bone. A score of 0 in either the hand or foot joints indicates no erosion.
LSM was calculated using an MMRM model with treatment, baseline value, visit, and the interactions of baseline-by-visit and treatment-by-visit as fixed factors.Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR20 Year 5 after entry into JADY ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants analyzed) \* 100
Change From Baseline of Originating Study in Modified Total Sharp Score (mTSS) Baseline, Year 5 X-rays of the hands/wrists and feet were scored for structural progression as measured using the mTSS. This methodology quantified the extent of bone erosions and joint space narrowing (JSN) for 44 and 42 joints, with higher scores representing greater damage. The mTSS at a time point is the sum of the erosion (range from 0 to 280) and JSN (range from 0 to 168) scores, for a maximum score of 448. Least Squares Mean (LSM) was calculated using a mixed model for repeated measures (MMRM) with treatment, visit, treatment-by-visit-interactions as fixed categorical effects and baseline and baseline-by-visit-interactions as fixed continuous effects.
Percentage of Participants With mTSS Change ≤0 Year 5 after entry into JADY X-rays of the hands/wrists and feet were scored for structural progression as measured using the mTSS. This methodology quantified the extent of bone erosions and joint space narrowing (JSN) for 44 and 42 joints, with higher scores representing greater damage. The mTSS at a time point is the sum of the erosion (range from 0 to 280) and JSN (range from 0 to 168) scores, for a maximum score of 448, with higher scores representing greater damage.
Change From Baseline of Originating Study in Joint Space Narrowing at Year 5 Baseline, Year 5 X-rays of the hands/wrists and feet were assessed for joint space narrowing (JSN) and bone erosions. Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, is scored from 0 to 4, with 0 indicating no (normal) JSN and 4 indicating complete loss of joint space, bony ankylosis or luxation. JSN scores ranged from 0-168. A score of 0 would indicate no change and higher scores represent a worsening of joint space narrowing
Change From Baseline of Originating Study in Duration of Morning Stiffness Baseline, Year 5 Participants reported the duration of their morning joint stiffness (MJS) in hours and minutes. The participants were asked about their duration of morning joint stiffness on the day prior to the study visit to capture actual symptoms, since the participant may have had an atypical morning routine on the day of the study visit. If morning joint stiffness duration was longer than 12 hours (720 minutes), it was truncated to 720 minutes for statistical presentations and analyses. A decrease in duration of morning joint stiffness indicated an improvement in the participant's condition.
Change From Baseline of Originating Study in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Health State Scores Baseline, Year 5 The European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. The first component is a descriptive system of the respondent's health comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.594 to 1, and the United States (US) algorithm, with scores ranging from -0.109 to 1. A higher score indicates better health state.
Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR50 Year 5 after entry into JADY ACR50 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR50 Responder is a participant who had ≥50% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥50% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Percentage of participants achieving ACR50 response = (number of ACR50 responders) / (number of participants analyzed) \* 100
Percentage of Participants Maintaining an American College of Rheumatology (ACR) Response of ACR70 Year 5 after entry into JADY ACR70 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR70 Responder is a participant who had ≥70% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥70% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Percentage of participants achieving ACR70 response = (number of ACR70 responders) / (number of participants analyzed) \* 100
Percentage of Participants Maintaining a Disease Activity Score (DAS28) High-Sensitivity C-Reactive Protein (hsCRP) ≤3.2 Year 5 after entry into JADY Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count-28 (TJC28), swollen joint count-28 (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*patient's global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity, low disease activity was DAS28-CRP ≤3.2 and remission was DAS28-CRP \<2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition.
Percentage of Participants Maintaining a Disease Activity Score (DAS28) High-Sensitivity C-Reactive Protein (hsCRP)<2.6 Year 5 after entry into JADY Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count-28 (TJC28), swollen joint count-28 (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*patient's global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity, low disease activity was DAS28-CRP ≤3.2 and remission was DAS28-CRP \<2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition.
Percentage of Participants Maintaining a DAS28-Erythrocyte Sedimentation Rate (ESR) Score of ≤3.2 Year 5 after entry into JADY DAS28 consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), ESR (millimeters per hour), and Patient's Global Assessment of Disease Activity. DAS28 was calculated using following formula: DAS28-ESR=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.70\*natural log(ESR)+0.014\*Patient's Global VAS. Total scores ranged from 1.0-9.4, where lower scores indicated less disease activity.
Percentage of Participants Maintaining a DAS28-Erythrocyte Sedimentation Rate (ESR) Sore of <2.6 Year 5 after entry into JADY DAS28 consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), ESR (millimeters per hour), and Patient's Global Assessment of Disease Activity. DAS28 was calculated using following formula: DAS28-ESR=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.70\*natural log(ESR)+0.014\*Patient's Global VAS. Total scores ranged from 1.0-9.4, where lower scores indicated less disease activity.
Change From Baseline of Originating Study in Joint Space Narrowing at Year 3 Baseline, Year 3 X-rays of the hands/wrists and feet were assessed for joint space narrowing (JSN) and bone erosions. Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, is scored from 0 to 4, with 0 indicating no (normal) JSN and 4 indicating complete loss of joint space, bony ankylosis or luxation. JSN scores ranged from 0-168. A score of 0 would indicate no change and higher scores represent a worsening of joint space narrowing.
Percentage of Participants Maintaining a Clinical Disease Activity Index Score (CDAI) ≤2.8 Year 5 after entry into JADY The CDAI is a tool for measurement of disease activity in RA that does not require a laboratory component and was scored by the investigative site. It integrates TJC28 (scored 0-28 with higher scores indicating higher disease activity), SJC28 (scored 0-28 with higher scores indicating higher disease activity), Patient's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity), and Physician's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity). The CDAI is calculated by summing the values of the 4 components. CDAI scores range from 0 to 76; lower scores indicated lower disease activity. A negative change from baseline indicates improvement in condition.
Healthcare Resource Utilization Baseline up to 84 Months Number of visits to medical care providers related to treatment of Rheumatoid Arthritis (RA) outside of the clinical study. Reported here are healthcare consultations and emergency room consultations from end of originating study to end of participation in study JADY.
Percentage of Participants Maintaining a Simplified Disease Activity Index (SDAI) ≤11 Year 5 after entry into JADY SDAI is a tool for measurement of disease activity in RA that integrates TJC28, SJC28, acute phase response using C-reactive protein (milligrams per liter), Patient's Global Assessment of Disease Activity using visual analog scale (cm), and Physician's Global Assessment of Disease Activity using visual analog scale (cm). The SDAI is calculated by summing the values of the 5 components. Lower scores indicated less disease activity.
The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). Low disease activity is defined as a SDAI score ≤11.Percentage of Participants Maintaining a Clinical Disease Activity Index Score (CDAI) ≤10 Years 5 after entry into JADY The CDAI is a tool for measurement of disease activity in RA that does not require a laboratory component and was scored by the investigative site. It integrates TJC28 (scored 0-28 with higher scores indicating higher disease activity), SJC28 (scored 0-28 with higher scores indicating higher disease activity), Patient's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity), and Physician's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity). The CDAI is calculated by summing the values of the 4 components. CDAI scores range from 0 to 76; lower scores indicated lower disease activity. A negative change from baseline indicates improvement in condition.
Percentage of Participants Maintaining a Clinical Disease Activity Index Score (CDAI) ≤ 2.8 Year 1 after entry into JADY The CDAI is a tool for measurement of disease activity in RA that does not require a laboratory component and was scored by the investigative site. It integrates TJC28 (scored 0-28 with higher scores indicating higher disease activity), SJC28 (scored 0-28 with higher scores indicating higher disease activity), Patient's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity), and Physician's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity). The CDAI is calculated by summing the values of the 4 components. CDAI scores range from 0 to 76; lower scores indicated lower disease activity. A negative change from baseline indicates improvement in condition.
Percentage of Participants Maintaining a Health Assessment Questionnaire Disability Index (HAQ-DI) Improvement ≥0.22 Year 5 after entry into JADY The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition. An improvement of 0.22 or 0.3 points on the HAQ-DI has been identified as a minimal clinically important difference in Rheumatoid Arthritis participants.
Percentage of Participants Maintaining a Simplified Disease Activity Index (SDAI) ≤3.3 Year 5 after entry into JADY SDAI is a tool for measurement of disease activity in RA that integrates TJC28, SJC28, acute phase response using C-reactive protein (milligrams per liter), Patient's Global Assessment of Disease Activity using visual analog scale (cm), and Physician's Global Assessment of Disease Activity using visual analog scale (cm). The SDAI is calculated by summing the values of the 5 components. Lower scores indicated less disease activity.
The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). Disease remission is defined as an SDAI score of ≤3.3.Percentage of Participants With Relapse Event During the 96-Week Step-Down Period Week 0 through Week 96 of Step-down Relapse is defined as a Clinical Disease Activity Index score \> 10. The CDAI is a tool for measurement of disease activity in RA that does not require a laboratory component and was scored by the investigative site. It integrates TJC28 (scored 0-28 with higher scores indicating higher disease activity), SJC28 (scored 0-28 with higher scores indicating higher disease activity), Patient's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity), and Physician's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity). The CDAI is calculated by summing the values of the 4 components. CDAI scores range from 0 to 76; lower scores indicated lower disease activity.
Total number of participants at risk multiplied by estimate of cumulative event probability would need to be rounded up or down to get a whole number.
Trial Locations
- Locations (407)
Hippokration Hospital of Athens
🇬🇷Athens, Attiki, Greece
University General Hospital of Larissa
🇬🇷Larissa, Greece
Diagnostic Rheumatology and Research
🇺🇸Indianapolis, Indiana, United States
Indiana University Health
🇺🇸Indianapolis, Indiana, United States
Goldpoint Clinical Research LLC
🇺🇸Indianapolis, Indiana, United States
Hadassah Medical Center
🇮🇱Jerusalem, Israel
Centrum Badan Klinicznych PI-House sp. z o.o.
🇵🇱Gdansk, Pomorskie, Poland
REUMATIKA - Centrum Reumatologii
🇵🇱Warszawa, Poland
New England Research Associates
🇺🇸Bridgeport, Connecticut, United States
Arizona Arthritis & Rheumatology Research, PLLC
🇺🇸Glendale, Arizona, United States
Clinical Research Center of CT/NY
🇺🇸Danbury, Connecticut, United States
Desert Medical Advances
🇺🇸Palm Desert, California, United States
Delaware Arthritis
🇺🇸Lewes, Delaware, United States
Medallion Clinical Research Institute
🇺🇸Naples, Florida, United States
Valley Endocrine, Fresno
🇺🇸Fresno, California, United States
Arizona Arthritis & Rheumatology Associates, P. C.
🇺🇸Mesa, Arizona, United States
Pioneer Research Solutions
🇺🇸Cypress, Texas, United States
Stanford University Hospital
🇺🇸Palo Alto, California, United States
Ocean Rheumatology, PA
🇺🇸Toms River, New Jersey, United States
Arthritis & Osteoporosis Associates LLP
🇺🇸Lubbock, Texas, United States
Klein and Associates MD, PA
🇺🇸Cumberland, Maryland, United States
Sun Valley Arthritis Center, LTD
🇺🇸Peoria, Arizona, United States
Inland Rheumatology & Osteoporosis Medical Group
🇺🇸Upland, California, United States
Drug Trials of America
🇺🇸Hartsdale, New York, United States
Dr. George Timothy Kelly
🇺🇸Las Vegas, Nevada, United States
Intermountain Research Center
🇺🇸Boise, Idaho, United States
Boulder Medical Center
🇺🇸Boulder, Colorado, United States
Pacific Arthritis Center
🇺🇸Santa Maria, California, United States
West Broward Rheumatology Associates, Inc
🇺🇸Tamarac, Florida, United States
Albuquerque Clinical Trials, Inc.
🇺🇸Albuquerque, New Mexico, United States
Allergy and Rheumatology Medical Clinic Inc
🇺🇸La Jolla, California, United States
Advanced Rheumatology, PC
🇺🇸Lansing, Michigan, United States
Office: Dr. Fiechtner, Justus
🇺🇸Lansing, Michigan, United States
Orthopedic Research Institute
🇺🇸Boynton Beach, Florida, United States
Sun Coast Clinical Research, Inc
🇺🇸New Port Richey, Florida, United States
Deerbrook Medical Associates
🇺🇸Vernon Hills, Illinois, United States
Carolina Rheumatology and Neurology Associates
🇺🇸Myrtle Beach, South Carolina, United States
Arthritis Research of Florida
🇺🇸Palm Harbor, Florida, United States
University of Missouri
🇺🇸Columbia, Missouri, United States
Asheville Rheumatology & Osteoporosis Research Assoc, PA
🇺🇸Asheville, North Carolina, United States
The Center for Rheumatology
🇺🇸Albany, New York, United States
St Vincents Hospital Melbourne
🇦🇺Fitzroy, Victoria, Australia
Kadlec Clinic Rheumatology
🇺🇸Kennewick, Washington, United States
Clayton Medical Research
🇺🇸Saint Louis, Missouri, United States
Healthcare Research Consultant
🇺🇸Tulsa, Oklahoma, United States
Centro de Investigaciones Medicas Mar del Plata
🇦🇷Mar del Plata, Buenos Aires, Argentina
CER Instituto Medico
🇦🇷Quilmes, Buenos Aires, Argentina
Arthritis Group
🇺🇸Philadelphia, Pennsylvania, United States
Borgess Rheumatology
🇺🇸Kalamazoo, Michigan, United States
Allergy Asthma Immunology of Rochester, AAIR Research Ctr
🇺🇸Rochester, New York, United States
The Vancouver Clinic
🇺🇸Vancouver, Washington, United States
Rheumatology and Immunotherapy Center
🇺🇸Franklin, Wisconsin, United States
CENIT Centro de Neurociencias, Investigación y Tratamiento
🇦🇷Caba, Ciudad Autonoma Buenos Aires, Argentina
Arthritis Consultants, Inc.
🇺🇸Saint Louis, Missouri, United States
Centro De Osteopatias - Comlit
🇦🇷Ciudad Autonoma de Buenos Aire, Argentina
Dr. Rethy Pal Korhaz es Rendelointezet
🇭🇺Bekescsaba, Bekes, Hungary
PerCuro Clinical Research Ltd.
🇨🇦Victoria, British Columbia, Canada
Western Washington Arthritis Clinic
🇺🇸Bothell, Washington, United States
CCBR Buenos Aires
🇦🇷Ciudad Autonoma de Buenos Aire, Argentina
Hospital Privado Centro Medico de Cordoba SA
🇦🇷Cordoba, Argentina
CHU Ambroise Pare
🇧🇪Mons, Belgium
Metroplex Clinical Research Center
🇺🇸Dallas, Texas, United States
Mount Sinai Hospital
🇨🇦Toronto, Ontario, Canada
Center for Arthritis and Rheumatic Diseases, PC
🇺🇸Chesapeake, Virginia, United States
Rheumatology Research Associates Group
🇨🇦Edmonton, Alberta, Canada
Saskatoon Osteoporosis Centre
🇨🇦Saskatoon, Saskatchewan, Canada
Combined Rheumatology Practice (CRP)
🇦🇺Kogarah, New South Wales, Australia
Centro de Medicina Familiar Mindout Research
🇦🇷Ciudad Autonoma de Buenos Aire, Argentina
Instituto Medico de Alta Complejidad San Isidro
🇦🇷San Isidro, Buenos Aires, Argentina
CEPIC - Centro Paulista de Investigação Clínica
🇧🇷São Paulo, SP, Brazil
Cent Priva Especiali Médicas Ambulatorias Inve Clin CEMAIC
🇦🇷Cordoba, Argentina
Centre de Recherche Musculo-Squelettique
🇨🇦Trois-Rivieres, Quebec, Canada
The Second Xiangya Hospital of Central South University
🇨🇳Changsha, Hunan, China
KW Musculoskeletal Research Inc
🇨🇦Kitchener, Ontario, Canada
ZNA Jan Palfijn
🇧🇪Merksem, Vlaams Gewest, Belgium
Centro Medico Privado de Reumatologia
🇦🇷SAN M. DE Tucuman, Tucumán, Argentina
Center de Recherche St Louis
🇨🇦Quebec City, Quebec, Canada
Hospital Italiano Regional del Sur
🇦🇷Bahia Blanca, Buenos Aires, Argentina
Consultorios Asociados de Endocrinologia
🇦🇷Ciudad Autonoma Buenos Aires, Argentina
Instituto Centenario
🇦🇷Caba, Ciudad Autonoma De Buenos Aire, Argentina
The Ottawa Hospital
🇨🇦Ottawa, Ontario, Canada
Peking University People's Hospital
🇨🇳Beijing, Beijing, China
Universitätsklinikum Graz
🇦🇹Graz, Steiermark, Austria
Rheuma Zentrum Favoriten GmbH
🇦🇹Wien, Austria
Revita Clinic
🇭🇺Budapest, Pest, Hungary
CPCLIN
🇧🇷São Paulo, SP, Brazil
Klinicka bolnica Sveti Duh
🇭🇷Zagreb, Croatia
KLES Prabhakar Kore Hospital and Medical Research Centre
🇮🇳Belgaum, Karnataka, India
Manitoba Clinic Medical Corporation
🇨🇦Winnipeg, Manitoba, Canada
Vesalion s.r.o.
🇨🇿Ostrava, Czechia
Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz
🇭🇺Szekesfehervar, Fejer, Hungary
Anhui Provincial Hospital
🇨🇳Hefei, Anhui, China
Sumana Hospital
🇮🇳Hyderabad, Andhra Pradesh, India
NTT East Japan Sapporo Hospital
🇯🇵Sapporo, Hokkaido, Japan
General Hospital of Attica KAT
🇬🇷Kifissia, Attiki, Greece
Shalby Hospital
🇮🇳Ahmedabad, Gujarat, India
Medanta-The Medicity
🇮🇳Gurgaon, Haryana, India
University General Hospital of Heraklion
🇬🇷Heraklion, Crete, Greece
Ospedale Policlinico Giambattista Rossi, Borgo Roma
🇮🇹Verona, Italy
Barzilai Medical Center
🇮🇱Ashkelon, HaDarom, Israel
ARTHROHELP s.r.o.
🇨🇿Pardubice, Czechia
Szabolcs-Szatmar-Bereg M-i Korhazak es Egyetemi Oktatokorhaz
🇭🇺Nyiregyhaza, Szabolcs-Szatmar-Bereg, Hungary
Tel Aviv Sourasky Medical Center
🇮🇱Tel Aviv, Israel
Katayama Clinic
🇯🇵Asahikawa, Hokkaido, Japan
Hokkaido University Hospital
🇯🇵Sapporo, Hokkaido, Japan
CSM Medical University
🇮🇳Lucknow, Uttar Pradesh, India
Azienda Ospedaliera Universitaria Careggi
🇮🇹Firenze, Italy
Oasis Clinic
🇯🇵Hitachi, Ibaragi, Japan
CHU la Miletrie
🇫🇷Poitiers, France
Ospedale Luigi Sacco
🇮🇹Milano, Italy
Kiskunhalasi Semmelweis Korhaz
🇭🇺Kiskunhalas, Bacs-Kiskun, Hungary
Csolnoky Ferenc Korhaz
🇭🇺Veszprem, Hungary
Stabilimento Ospedaliero Santa Chiara
🇮🇹Pisa, Italy
Manipal Centre for Clinical Research (MCCR)
🇮🇳Attavar, Mangalore, Karnataka, India
St. John Medical College & Hospital
🇮🇳Bangalore, Karnataka, India
Care Hospital
🇮🇳Hyderabad, Telangana, India
Ospedale San Giovanni Bosco
🇮🇹Torino, Italy
Tsukuba University Hospital
🇯🇵Tsukuba, Ibaraki, Japan
Yoshitama Clinic Rheumatology & Internal Medicine
🇯🇵Kirishima, Kagoshima, Japan
Indraprastha Apollo Hospital
🇮🇳New Delhi, Delhi, India
Kokilaben Dhirubhai Ambani Hospital &Medical Research Inst.
🇮🇳Mumbai, Maharashtra, India
Nagoya Medical Center
🇯🇵Nagoya, Aichi, Japan
Fujimori Clinic
🇯🇵Hachioji, Tokyo, Japan
Kagawa University Hospital
🇯🇵Kita-gun, Kagawa, Japan
National Nagasaki Medical Center
🇯🇵Omura, Nagasaki, Japan
Rabin Medical Center
🇮🇱Petah Tiqva, Israel
Chubu-Rosai Hospital
🇯🇵Nagoya, Aichi, Japan
Hiroshima Clinic
🇯🇵Hiroshima, Japan
Ajou University Hospital
🇰🇷Suwon, Gyeonggi-do, Korea, Republic of
Keio University Hospital
🇯🇵Shinjuku-Ku, Tokyo, Japan
Yoshida Orthopaedic and Rheumatic Clinic
🇯🇵Morioka, Iwate, Japan
Nagano Red Cross Hospital
🇯🇵Nagano, Japan
St. Lukes International Hospital
🇯🇵Chuo-Ku, Tokyo, Japan
Japanese Red Cross Okayama Hospital
🇯🇵Okayama, Japan
Kyunghee University Hospital at Gangdong
🇰🇷Seoul, Korea, Korea, Republic of
Kumamoto Rheumatology Clinic
🇯🇵Kumamoto, Japan
Dr. Sarmite Saleniece
🇱🇻Valmiera, Latvia
Respublikine Siauliu Ligonine
🇱🇹Siauliai, Lithuania
Takaoka Rheumatic Orthopedic CL
🇯🇵Takaoka, Toyama, Japan
Chungnam National University Hospital
🇰🇷Daejeon, Korea, Korea, Republic of
Catholic University of Korea Yeouido St. Mary's Hospital
🇰🇷Seoul, Korea, Korea, Republic of
Nagasaki Medical Hospital of Rheumatology
🇯🇵Nagasaki, Japan
Kondo Clinic for Rheumatism and Orthopaedics
🇯🇵Fukuoka, Japan
Kumamoto Shinto General hospital
🇯🇵Kumamoto, Japan
Tokyo Women's Medical University East Medical Center
🇯🇵Arakawa-ku, Tokyo, Japan
Kyung Pook National University Hospital
🇰🇷Daegu, Korea, Korea, Republic of
China Medical University Hospital
🇨🇳Taichung City, Taiwan
Asan Medical Center
🇰🇷Seoul, Korea, Korea, Republic of
Seoul St. Mary's Hospital
🇰🇷Seoul, Korea, Korea, Republic of
Unidad de Investigacion en Enfermedades Cronico Degenerative
🇲🇽Guadalajara, Jalisco, Mexico
Hospital de Jesus I.A.P.
🇲🇽Mexico City, Distrito Federal, Mexico
Centrum Medyczne Pratia Katowice
🇵🇱Katowice, Poland
Reumacentrum s.r.o.
🇸🇰Partizanske, Slovakia
Chang Gung Memorial Hospital - Kaohsiung Branch
🇨🇳Kaohsiung City, Taiwan
Latin Clinical Trial Center
🇵🇷San Juan, Puerto Rico
Hospital Quiron Infanta Luisa
🇪🇸Sevilla, Andalucía, Spain
Winelands Medical Research Centre
🇿🇦Stellenbosch, Western Cape, South Africa
Hospital Universitario Getafe
🇪🇸Getafe, Madrid, Spain
CHUV Centre Hospitalier Universitaire Vaudois
🇨🇭Lausanne, Vaud, Switzerland
Hospital Universitario Virgen Macarena
🇪🇸Sevilla, Spain
Chi-Mei Medical Center
🇨🇳Yongkang City, Taiwan
CHRU de Limoges Hopital Dupuytren
🇫🇷Limoges CEDEX, Haute-Vienne, France
Shri Nidan Hospital & Hope Fertility Centre
🇮🇳Jaipur, Rajasthan, India
Arizona Research Center
🇺🇸Phoenix, Arizona, United States
Health Research of Oklahoma
🇺🇸Oklahoma City, Oklahoma, United States
Copenhagen University Hospital
🇩🇰Glostrup, Hovedstaden, Denmark
Odense Universitetshospital
🇩🇰Odense C, Syd, Denmark
The First Affiliate Hospital of AnHui Medical University
🇨🇳Hefei, Anhui, China
1st Hospital affiliated to Medical College of Shantou Univer
🇨🇳Shantou, Guangzhou, China
ZhuZhou Central Hospital
🇨🇳ZhuZhou, Hunan, China
YanCheng First People's Hospital
🇨🇳Yancheng, Jiangsu, China
West China Hospital Sichuan University
🇨🇳Cheng Du, Sichuan, China
Zhongshan Hospital, Fudan University
🇨🇳Shanghai, Shanghai, China
Polic.Umberto I -Univ. La Sapienza
🇮🇹Roma, Italy
Denver Arthritis Clinic - Lowry
🇺🇸Denver, Colorado, United States
Oregon Health and Science University
🇺🇸Portland, Oregon, United States
UHN-Toronto Western Hospital
🇨🇦Toronto, Ontario, Canada
National Chiba-East-Hospital
🇯🇵Chuo-ku, Chiba, Japan
Hokkaido Medical Center for Rheumatic Diseases
🇯🇵Sapporo, Hokkaido, Japan
Matsubara Mayflower Hospital
🇯🇵Kato, Hyogo, Japan
Komagamine Orthopedic and Rheumatology Clinic
🇯🇵Morioka, Iwate, Japan
St Marianna University School of Medicine Hospital
🇯🇵Kawasaki, Kanagawa, Japan
Tsuzuki Azuma Clinic: Primary care and Rheumatology
🇯🇵Yokohama-City, Kanagawa, Japan
Yokkaichi Hazu Medical Center
🇯🇵Yokkaichi, Mie, Japan
Yokohama City University Hospital
🇯🇵Yokohama, Kanagawa, Japan
Nagaoka Red Cross Hospital
🇯🇵Nagaoka, Niigata, Japan
Azuma Rheumatology Clinic
🇯🇵Sayama, Saitama, Japan
Kaneko Clinic
🇯🇵Kawaguchi, Saitama, Japan
Jichi Medical University Hospital
🇯🇵Shimotsuke, Tochigi, Japan
Hirose Clinic
🇯🇵Tokorozawa, Saitama, Japan
Miyasato Clinic
🇯🇵Shunan, Yamaguchi, Japan
National Hospital Organization Kyushu Medical Center
🇯🇵Fukuoka, Japan
Medical Co. LTA Fukuoka Mirai Hospital
🇯🇵Fukuoka, Japan
Kagoshima Red Cross Hospital
🇯🇵Kagoshima, Japan
The Japanese Red Cross Nagasaki Genbaku Hospital
🇯🇵Nagasaki, Japan
Okayama Saiseikai General Hospital Outpatient Center
🇯🇵Okayama, Japan
Okayama University Hospital
🇯🇵Okayama, Japan
Yokota Clinic for Rheumatology
🇯🇵Osaka, Japan
Shizuoka Rheumatism orthopedic Rehabilitation Hospital
🇯🇵Shizuoka, Japan
JA-Shizuoka Shizuoka-Kosei General Hospital
🇯🇵Shizuoka, Japan
Städtisches Klinikum Dresden-Friedrichstadt
🇩🇪Dresden, Sachsen, Germany
CEMIC Saavedra
🇦🇷Ciudad Autonoma de Buenos Aire, Argentina
CENUDIAB
🇦🇷Ciudad Autonoma de Buenos Aire, Argentina
Instituto Medico Strusberg
🇦🇷Cordoba, Argentina
Consultorios Reumatologicos Pampa
🇦🇷Ciudad Autonoma de Buenos Aire, Argentina
Hospital Italiano de Cordoba
🇦🇷Cordoba, Argentina
Orszagos Reumatologiai es Fizioterapias Intezet
🇭🇺Budapest, Hungary
Seirei Hamamatsu General Hospital
🇯🇵Hamamatsu, Shizuoka, Japan
University of Arizona
🇺🇸Tucson, Arizona, United States
Arthritis and Osteporosis Treatment and Research Center
🇺🇸Flowood, Mississippi, United States
West Michigan Rheumatology
🇺🇸Grand Rapids, Michigan, United States
(AOA) Arthritis & Osteoporosis Associates
🇺🇸Freehold, New Jersey, United States
Arthritis and Osteoporosis Consultants of the Carolinas
🇺🇸Charlotte, North Carolina, United States
East Penn Rheumatology Associates
🇺🇸Bethlehem, Pennsylvania, United States
Altoona Center For Clinical Research
🇺🇸Duncansville, Pennsylvania, United States
Paramount Medical Research
🇺🇸Middleburg Heights, Ohio, United States
Clinical Research Center of Reading,LLC
🇺🇸Wyomissing, Pennsylvania, United States
Accurate Clinical Research
🇺🇸Webster, Texas, United States
Atencion Integral en Reumatología
🇦🇷Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina
Instituto de Investigaciones Clínicas Mar del Plata
🇦🇷Mar del Plata, Buenos Aires, Argentina
Instituto de Investigaciones Clinicas Quilmes
🇦🇷Quilmes, Buenos Aires, Argentina
Centro de Enfermedades del Higado y Aparato Digestivo
🇦🇷Rosario, Santa Fe, Argentina
Instituto CAICI SRL
🇦🇷Rosario, Santa Fe, Argentina
Organizacion Medica de Investigacion - OMI
🇦🇷Ciudad Autonoma de Buenos Aire, Argentina
Hospital Ramos Mejia
🇦🇷Ciudad Autonoma de Buenos Aire, Argentina
CIR Centro de Investigacions Reumatologicas
🇦🇷San Miguel de Tucuman, Tucuman, Argentina
Canberra Hospital
🇦🇺Garran, Australian Capital Territory, Australia
Centro Polivalente de Asistencia e Inv. Clinica CER-San Juan
🇦🇷San Juan, Argentina
Emeritus Research
🇦🇺Camberwell, Victoria, Australia
Coast Joint Care
🇦🇺Maroochydore, Queensland, Australia
Royal Prince Alfred Hospital
🇦🇺Camperdown, New South Wales, Australia
Cliniques Universitaires Saint-Luc
🇧🇪Bruxelles, Brussel, Belgium
Universitair Ziekenhuis Gent
🇧🇪Gent, Oost-Vlaanderen, Belgium
Niagara Peninsula Arthritis Centre, Inc.
🇨🇦St. Catherines, Ontario, Canada
Afflilated Hospital of Bengbu Medical College
🇨🇳Bengbu, Anhui, China
Guangdong Provincial People's Hospital
🇨🇳Guangzhou, Guangdong, China
Xiangya Hospital, Central South University
🇨🇳Changsha, Hunan, China
Pingxiang People's Hospital
🇨🇳Pingxiang, Jiangxi, China
China-Japan Friendship Hospital
🇨🇳Beijing, China
Qilu Hospital of Shandong University
🇨🇳Jinan, Shandong, China
First Affiliated Hospital of Kunming Medical University
🇨🇳Kunming, Yunnan, China
KBC Osijek
🇭🇷Osijek, Croatia
Ningbo First Hospital
🇨🇳Ningbo, Zhejiang, China
Shanghai Guanghua Hospital
🇨🇳Shanghai, China
Revmatologicky ustav
🇨🇿Praha 2, Praha, Hlavní Mešto, Czechia
Revmaclinic, s.r.o
🇨🇿Brno, Czechia
Revmatologicka ambulance
🇨🇿Bruntal, Czechia
Poliklinika K-centar
🇭🇷Zagreb, Croatia
ELIMATES BRNO s.r.o. Revmatologicka ambulance
🇨🇿Hustopece, Czechia
Artroscan, s.r.o.
🇨🇿Ostrava, Czechia
Medical Plus
🇨🇿Uherske Hradiste, Czechia
PV Medical Services s.r.o.
🇨🇿Zlin, Czechia
Frederiksberg Hospital
🇩🇰Frederiksberg, Hovedstaden, Denmark
Centre Hospitalier Jean Rougier
🇫🇷Cahors CEDEX 9, France
Hôpital Trousseau, CHRU de Tours
🇫🇷Chambray-lès-Tours, France
Hôpital Arnaud de Villeneuve - CHU Montpellier
🇫🇷Montpellier Cedex 5, France
Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu
🇫🇷Nantes Cedex 1, France
Nouvel Hôpital Orléans La Source
🇫🇷Orleans CEDEX 2, France
Hopital de la Pitie Salpetriere
🇫🇷Paris CEDEX 13, France
Hopital Cochin
🇫🇷Paris CEDEX 14, France
Universitätsklinikum Heidelberg
🇩🇪Heidelberg, Baden-Württemberg, Germany
Hopital Bel Air
🇫🇷Thionville, France
CHU Rennes/Hopital Sud
🇫🇷Rennes CEDEX 2, France
Klinikum der Universität München
🇩🇪München, Bayern, Germany
Internistisch-rheumatologische Praxisgemeinschaft Bayreuth
🇩🇪Bayreuth, Bayern, Germany
Immunologisches Zentrum Vogelsang-Gommern GmbH
🇩🇪Gommern, Sachsen-Anhalt, Germany
Universitätsklinikum Würzburg A. ö. R.
🇩🇪Würzburg, Bayern, Germany
Universitätsklinikum Köln
🇩🇪Köln, Nordrhein-Westfalen, Germany
Charité Campus Virchow-Klinikum
🇩🇪Berlin, Germany
M S Ramaiah Medical College Hospital
🇮🇳Bangalore, Karnataka, India
Krishna Institute of Medical Sciences Ltd.
🇮🇳Secunderabad, Telengana, India
Rambam Health Care Campus
🇮🇱Haifa, Israel
Assaf Harofeh Medical Center
🇮🇱Zerifin, Israel
Meir Medical Center
🇮🇱Kfar Saba, Israel
Carmel Hospital
🇮🇱Haifa, Ḥeifā, Israel
Nagoya University Hospital
🇯🇵Nagoya, Aichi, Japan
Matsudo City Hospital
🇯🇵Matsudo, Chiba, Japan
Chibaken Saiseikai Narashino Hospital
🇯🇵Narashino, Chiba, Japan
PS Clinic
🇯🇵Hakata-ku, Fukuoka, Japan
Shimoshizu National Hospital
🇯🇵Yotsukaido, Chiba, Japan
Aso Iizuka Hospital
🇯🇵Iizuka, Fukuoka, Japan
University of Occupational and Enviromental Health
🇯🇵Kitakyushu, Fukuoka, Japan
National Hospital Organization Asahikawa Medical Center
🇯🇵Asahikawa, Hokkaido, Japan
Sagawa Akira Rheumatology Clinic
🇯🇵Sapporo, Hokkaido, Japan
Takarazuka City Hospital
🇯🇵Takarazuka, Hyogo, Japan
Kumamoto Saishun Medical Center
🇯🇵Koshi, Kumamoto, Japan
Yokohama Minami Kyosai Hospital
🇯🇵Yokohama, Kanagawa, Japan
Tokai University Hospital
🇯🇵Isehara, Kanagawa, Japan
Yokohama Rosai Hospital
🇯🇵Yokohama, Kanagawa, Japan
Sasebo Chuo Hospital
🇯🇵Sasebo, Nagasaki, Japan
Osafune Clinic
🇯🇵Setouchi, Okayama, Japan
Niigata Rheumatic Center
🇯🇵Shibata, Niigata, Japan
Tomishiro Central Hospital
🇯🇵Tomigusuku, Okinawa, Japan
NHO Ureshino Medical Center
🇯🇵Ureshino, Saga, Japan
Nihon University Itabashi Hospital
🇯🇵Itabashi-ku, Tokyo, Japan
National Tokyo Medical Center
🇯🇵Meguro-Ku, Tokyo, Japan
Saitama Medical Center
🇯🇵Kawagoe, Saitama, Japan
Kyorin University Hospital
🇯🇵Mitaka, Tokyo, Japan
Hiroshima Rheumatology Clinic
🇯🇵Hiroshima, Japan
Shono Rheumatism Clinic
🇯🇵Fukuoka, Japan
Kumamoto Orthopedic Hospital
🇯🇵Kumamoto, Japan
Oribe Clinic Rheumatism and Medicine
🇯🇵Oita, Japan
Daegu Catholic University Medical Center
🇰🇷Daegu, Korea, Korea, Republic of
Chonnam National University Hospital
🇰🇷Gwangju, Korea, Korea, Republic of
Inha University Hospital
🇰🇷Incheon, Korea, Korea, Republic of
Seoul National University Hospital
🇰🇷Seoul, Korea, Korea, Republic of
Gachon University Gil Medical Center
🇰🇷Incheon, Korea, Korea, Republic of
Kyung Hee University Hospital
🇰🇷Seoul, Korea, Korea, Republic of
Hanyang University Medical Center
🇰🇷Seoul, Korea, Korea, Republic of
Konkuk University Medical Center
🇰🇷Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of
Seoul Municipal Boramae Hospital
🇰🇷Seoul, Korea, Korea, Republic of
Pauls Stradins Kliniska Universitates Slimnica
🇱🇻Riga, Latvia
Dr. Kildos Klinika
🇱🇹Kaunas, Lithuania
RM Pharma Specialists S.A. de C.V.
🇲🇽Mexico City, Distrito Federal, Mexico
Centro Integral en Reumatologia SA de CV
🇲🇽Guadalajara, Jalisco, Mexico
Hospital Universitario de Monterrey
🇲🇽Monterrey, Nuevo Leon, Mexico
Centro Medico de las Americas
🇲🇽Merida, Yucatan, Mexico
Centro de Alta Especialidad Reumatologia e Inv Potosi, S.C.
🇲🇽San Luis Potosi, Mexico
Medical Care and Research, S.A. de C.V.
🇲🇽Merida, Yucatan, Mexico
Ziekenhuisgroep Twente, Almelo
🇳🇱Almelo, Netherlands
Centrum Terapii Wspolczesnej J. M. Jasnorzewska Spolka Komandytowo-Akcyjna
🇵🇱Lodz, Poland
NZOZ Lecznica MAK-MED s.c.
🇵🇱Nadarzyn, Poland
Centrum Medyczne AMED
🇵🇱Warszawa, Poland
Hospital Garcia da Orta
🇵🇹Almada, Portugal
Instituto Portugues de Reumatologia
🇵🇹Lisbon, Portugal
Hospital do Conde de Bertiandos
🇵🇹Ponte de Lima, Portugal
Hospital de Sao Joao E.P.E.
🇵🇹Porto, Portugal
Ramon L. Ortega Colon
🇵🇷Carolina, Puerto Rico
Barbara Diaz Hernandez
🇵🇷San Juan, Puerto Rico
Mindful Medical Research
🇵🇷San Juan, Puerto Rico
Spitalul Clinic Sf Maria Bucuresti
🇷🇴Bucuresti, Romania
Spitalul Clinic de Recuperare Iasi
🇷🇴Iasi, Romania
Gbuz Lokb
🇷🇺Saint-Petersburg, Leningradskaya Oblast', Russian Federation
Spitalul Clinic Judetean de Urgenta Sf.Apostol Andrei Constanta
🇷🇴Constanta, Romania
City Clinical Hospital 1 named after N.I. Pirogov
🇷🇺Moscow, Russian Federation
V.A. Nasonova Research Institute of Rheumatology
🇷🇺Moscow, Russian Federation
GUZ UOKB
🇷🇺Ul'yanovsk, Ul'yanovskaya Oblast, Russian Federation
Family Clinic No 4
🇷🇺Korolev, Russian Federation
Ryazan Regional Clinincal Cardiology Dispensary
🇷🇺Ryazan, Russian Federation
Clinical Rheumatology Hospital # 25
🇷🇺St. Petersburg, Russian Federation
First Moscow State Medical University
🇷🇺Moscow, Russian Federation
Saratov Regional Clinical Hospital
🇷🇺Saratov, Russian Federation
Clinical Emergency Hospital N.V.Solovyov
🇷🇺Yaroslavl, Russian Federation
ROMJAN s.r.o.
🇸🇰Bratislava, Slovakia
Nestatna reumatologicka ambulancia
🇸🇰Bratislava, Slovakia
REUMED s.r.o.
🇸🇰Spisska Nova Ves, Slovakia
Bolnisnica Dr. P. Drzaja UKCLJ
🇸🇮Ljubljana, Slovenia
Precise Clinical Solutions (Pty) Ltd
🇿🇦Durban, KZ-Natal, South Africa
Netcare Greenacres Hospital
🇿🇦Port Elizabeth, Eastern Cape, South Africa
Saint Augustine's Hospital
🇿🇦Durban, KZ-Natal, South Africa
Hospital Universitario Marques De Valdecilla
🇪🇸Santander, Cantabria, Spain
Corporacion Sanitaria Parc Tauli
🇪🇸Sabadell, Barcelona, Spain
Somerset West Trial Centre
🇿🇦Somerset West, Western Cape, South Africa
Hospital Marina Baixa
🇪🇸La Vila Joiosa, Alicante, Spain
Hospital De Basurto
🇪🇸Bilbao, Vizcaya, Spain
Hospital Clinic I Provincial
🇪🇸Barcelona, Spain
Sahlgrenska Universitetssjukhuset
🇸🇪Göteborg, Gothenburg, Sweden
Hospital Universitario La Fe de Valencia
🇪🇸Valencia, Spain
Hospital de la Santa Creu i Sant Pau
🇪🇸Barcelona, Spain
Reumatologiska Kliniken Skånes universitetssjukhus Malmö
🇸🇪Malmo, Sweden
Universitätsspital Zürich
🇨🇭Zürich, Switzerland
HFR Fribourg - Hôpital Cantonal
🇨🇭Fribourg, Switzerland
Chung Shan Medical University Hospital
🇨🇳Taichung City, Taiwan
National Taiwan University Hospital
🇨🇳Taipei City, Taiwan
Cathay General Hospital
🇨🇳Taipei City, Taiwan
MacKay Memorial Hospital
🇨🇳Taipei City, Taiwan
Taipei Veterans General Hospital
🇨🇳Taipei City, Taiwan
Trakya University
🇹🇷Edirne, Turkey
Addenbrookes Hospital
🇬🇧Cambridge, Cambridgeshire, United Kingdom
Whipps Cross University Hospital
🇬🇧London, Surrey, United Kingdom
Southampton General Hospital
🇬🇧Southampton, Hants, United Kingdom
Basingstoke and North Hampshire Hospital
🇬🇧Basingstoke, Hampshire, United Kingdom
St Lukes Hospital
🇬🇧Bradford, West Yorkshire, United Kingdom
Arthritis Clinical Trial Centre
🇿🇦Cape Town, Western Cape, South Africa
Rheumatology Practice in Jaunliepaja Primary Health Care Cen
🇱🇻Liepaja, Latvia
Spital Clinic Judetean de Urgenta Tg.Mures
🇷🇴Tg.Mures, Mures, Romania
SC DUO Medical S.R.L Rheumatology
🇷🇴Bucuresti, Romania
Spitalul Clinic "Dr. Ioan Cantacuzino"
🇷🇴Bucuresti, Romania
IPGMER and SSKM Hospital
🇮🇳Kolkata, West Bengal, India
Associacao de Assistencia a Crianca Deficiente (AACD)
🇧🇷Sao Paulo, São Paulo, Brazil
Hospital Geral de Santo Antonio
🇵🇹Porto, Portugal
Klaipedos Universitetine Ligonine
🇱🇹Klaipeda, Lithuania
Tri-Service General Hospital
🇨🇳Neihu Taipei, Taiwan
Bnai Zion Medical Center
🇮🇱Haifa, Israel
Private Service
🇲🇽Guadalajara, Jalisco, Mexico
Apollo Gleneagles Hospitals Kolkata
🇮🇳Kolkata, West Bengal, India
Comite Mexicano para la Prevencion de la Osteoporosis A.C.
🇲🇽Mexico City, Distrito Federal, Mexico
Mentrials S.A. de C.V
🇲🇽Mexico City, Distrito Federal, Mexico
The Medical Arts Health Research Group
🇨🇦Kelowna, British Columbia, Canada
Mexico Centre for Clinical Research SA de CV
🇲🇽Mexico City, Distrito Federal, Mexico
LERAM s.r.o.
🇸🇰Topolcany, Slovakia
Clinica de Investigacion en Reumatologia y Obesidad S. C.
🇲🇽Guadalajara, Jalisco, Mexico
Centro de Estudios de Investigacion Basica y Clinica, S.C.
🇲🇽Guadalajara, Jalisco, Mexico
Ctro Inv en Artritis y Osteoporosis SC
🇲🇽Mexicali, Baja California, Mexico
Ponce School of Medicine CAIMED Center
🇵🇷Ponce, Puerto Rico
Szpital Uniwersytecki Nr 2 w Bydgoszczy, Klinika Reumatologii i Ukladowych Chorob Tkanki Lacznej
🇵🇱Bydgoszcz, Poland
Ambulatorium Barbara Bazela
🇵🇱Elblag, Poland
Reuma Clinic, Locatie Jaarbeurslaan
🇧🇪Genk, Belgium
Omega Research Consultants
🇺🇸Orlando, Florida, United States
Rheumatology Associates of Central Florida
🇺🇸Orlando, Florida, United States
AdventHealth Medical Group
🇺🇸Tampa, Florida, United States
Tampa Medical Group, P.A.
🇺🇸Tampa, Florida, United States
Sir Ganga Ram Hospital
🇮🇳New Delhi, Delhi, India
Centro de Investigacion del Noroeste
🇲🇽Tijuana, Baja California, Mexico
Schön Klinik Hamburg Eilbek
🇩🇪Hamburg, Germany
Northumbria Healthcare NHS Foundation Trust
🇬🇧Newcastle upon Tyne, Tyneside, United Kingdom
Guy's Hospital
🇬🇧London, Surrey, United Kingdom